 Early-onset Autosomal Dominant Alzheimer Disease
	Early-onset Autosomal Dominant Alzheimer Disease
Description
Early-onset autosomal dominant Alzheimer disease (EOAD) is a progressive dementia with reduction of cognitive functions. EOAD presents the same phenotype as sporadic Alzheimer disease (AD) but has an early age of onset, usually before 60 years old.
Genes related to Early-onset Autosomal Dominant Alzheimer Disease
- APP
- TREM2
- PSEN1
- ABCA7
- TOMM40
- PSEN2
- SORL1
Clinical Features
Top most frequent phenotypes and symptoms related to Early-onset Autosomal Dominant Alzheimer Disease
- Intellectual disability
- Seizures
- Ataxia
- Hypertonia
- Dementia
- Myoclonus
- Cerebral cortical atrophy
- Confusion
- Parkinsonism
- Memory impairment
And another 17 symptoms. If you need more information about this disease we can help you.
Incidence and onset information
— Currently we don't have prevalence information about this disease (Not enough data available about incidence and published cases.)— No data available about the known clinical features onset.
Alternative names
Early-onset Autosomal Dominant Alzheimer Disease Is also known as early-onset familial autosomal dominant alzheimer disease, eofad, familial alzheimer disease.
Researches and researchers
Doctors, researchs, and experts related to Early-onset Autosomal Dominant Alzheimer Disease extracted from public data.
Early-onset Autosomal Dominant Alzheimer Disease Experts map
Current Researchs and researchers
- 
 — Institution: Information not provided - DE — Institution: Information not provided - DE
 - 
Institution/s:
 — Institution: Information not provided - DE
- 
Research area/topic::JPND - CicProt: Protection of synaptic circuits by BDNF/TrkB and arc signalling pathways in mouse models of Alzheimer's dementia (AD) and Huntington's disease (HD) 
 
- 
Institution/s:
- 
Clinical expert - Principal investigator of clinical trial - Investigator of research project MÜNCHEN — Dr Johannes LEVIN MÜNCHEN — Dr Johannes LEVIN
 - 
Institution/s:
 — LMU Klinikum der Universität München - Campus Großhadern
 — DZNE-Standort München
- 
Research area/topic::Dominantly Inherited Alzheimer Network (DIAN) - DE 
 
- 
Institution/s:
- 
Investigator of research project - Coordinator of research network BRESCIA — Dr Giovanni FRISONI BRESCIA — Dr Giovanni FRISONI
 - 
Institution/s:
 — IRCCS Centro S.Giovanni di Dio - Fatebenefratelli
- 
Research area/topic::DIAN - Italian Network for autosomal dominant Alzheimer's disease and frontotemporal lobal degeneration 
 
- 
Institution/s:
- 
Responsible for diagnostic tests - Investigator of research project - Director of laboratory FIRENZE — Pr Sandro SORBI FIRENZE — Pr Sandro SORBI
 - 
Institution/s:
 — Dipartimento di Scienze Neurologiche e Psichiatriche, Azienda Ospedaliero Universitaria Careggi - NEUROFARBA
- 
Research area/topic::DIAN - Italian Network for autosomal dominant Alzheimer's disease and frontotemporal lobal degeneration 
 
- 
Institution/s:
- 
Investigator of research project FOGGIA — Dr Claudio BABILONI FOGGIA — Dr Claudio BABILONI
 - 
Institution/s:
 — Laboratorio di Patologia Generale, Azienda Ospedaliero Universitaria di Foggia - Ospedali Riuniti
- 
Research area/topic::DIAN - Italian Network for autosomal dominant Alzheimer's disease and frontotemporal lobal degeneration 
 
- 
Institution/s:
- 
Investigator of research project GENOVA — Dr Massimo TABATON GENOVA — Dr Massimo TABATON
 - 
Institution/s:
 — IRCCS AOU San Martino - IST - DINOGMI
- 
Research area/topic::Effects of Presenilin 1 mutationts on the beta-secretase cleavage of beta-amyloid precursor protein and on gene expression. The substrate of the phenotypic heterogeneity of familial Alzheimer's Disease 
 
- 
Institution/s:
- 
Investigator of research project MILANO — Dr Fabrizio TAGLIAVINI MILANO — Dr Fabrizio TAGLIAVINI
 - 
Institution/s:
 — Fondazione IRCCS Istituto Neurologico "Carlo Besta"
- 
Research area/topic::DIAN - Italian Network for autosomal dominant Alzheimer's disease and frontotemporal lobal degeneration 
 
- 
Institution/s:
- 
Investigator of research project PADOVA — Pr Rosario RIZZUTO PADOVA — Pr Rosario RIZZUTO
 - 
Institution/s:
 — Università degli Studi di Padova- Polo A.Vallisneri
- 
Research area/topic::Mitochondrial Ca2+ uptake in the pathogenesis of familial Alzheimer's disease 
 
- 
Institution/s:
- 
Clinical geneticist - Responsible for diagnostic tests - Investigator of research project SAN GIOVANNI ROTONDO — Dr Maria Grazia SAVINO SAN GIOVANNI ROTONDO — Dr Maria Grazia SAVINO
 - 
Institution/s:
 — Dipartimento di Patologia Clinica, IRCCS Ospedale Casa Sollievo della Sofferenza
 — Dipartimento di Scienze Mediche, IRCCS Ospedale Casa Sollievo della Sofferenza
- 
Research area/topic::Innovation and potential of microarray technology in genotyping applied to personalized therapy and identification of genotypes associated with drug treatment 
 
- 
Institution/s:
- 
Investigator of research project TRENTO — Dr Emiliano BIASINI TRENTO — Dr Emiliano BIASINI
 - 
Institution/s:
 — Centro Interdipartimentale per la Biologia Integrata, Università di Trento
- 
Research area/topic::Defining the role of the cellular prion protein at the intersection of several neurodegenerative diseases 
 
- 
Institution/s:
- 
Coordinator of expert centre - Genetic counsellor - Investigator of research project BARCELONA — Dr Raquel SÁNCHEZ DEL VALLE DÍAZ BARCELONA — Dr Raquel SÁNCHEZ DEL VALLE DÍAZ
 - 
Institution/s:
 — Servicio de Neurología, Hospital Clínic de Barcelona
 — Neurociencia clínica y experimental, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
- 
Research area/topic::Genetic dementia (autosomal dominant Alzheimer's disease and genetic prion diseases) in preclinical and early stages of the disease: cognitive performance, neuroimaging and biochemical markers 
 
- 
Institution/s:
- 
Investigator of research project BELLINZONA — Dr Maurizio MOLINARI BELLINZONA — Dr Maurizio MOLINARI
 - 
Institution/s:
 — Protein Folding and Quality Control - Institute for Research in Biomedicine, Istituto di Ricerca in Biomedicina
- 
Research area/topic::Investigating cellular mechanisms regulating protein folding and quality control to intervene in conformational diseases 
 
- 
Institution/s:
- 
Coordinator of research network CAMBRIDGE — Pr James FAWCETT CAMBRIDGE — Pr James FAWCETT
 - 
Institution/s:
 — University of Cambridge, John van Geest Centre for Brain Repair
- 
Research area/topic::EUNEURONE: European Consortium for Research in Neurodegenerative Diseases 
 
- 
Institution/s:
Early-onset Autosomal Dominant Alzheimer Disease Recommended genes panels
| Panel Name, Specifity and genes Tested/covered | 
|---|
|  MitoMet®Plus aCGH Analysis. By Baylor Miraca Genetics Laboratories (United States). 
RGS9, RHO, GRK1, RLBP1, RNASEL, BCS1L, RP1, RP2, RP9, RPE65, RPGR, RPL35A, MRPL3, RPS14, RS1, SAG, SARDH, SCO2, SCP2, SDHB	, (...)
 View the complete list with 612 more genes 
Specificity
 1 % 
Genes
 29 % | 
|  ADmark® APP DNA Sequencing/Duplication Test. By Athena Diagnostics Inc (United States). 
APP
 
Specificity
 100 % 
Genes
 15 % | 
|  ADmark® Early Onset Alzheimer's Evaluation. By Athena Diagnostics Inc (United States). 
APP, PSEN1, PSEN2
 
Specificity
 100 % 
Genes
 43 % | 
|  Dementia. By Knight Diagnostic Laboratories - Molecular Diagnostic Center Oregon Health & Science University (United States). 
SORL1, TARDBP, VCP, FIG4, OPTN, TREM2, CSF1R, CHMP2B, DCTN1, C9orf72, FUS, ALS2, SETX, GRN, ANG, APOE, APP, MAPT, PRNP, PSEN1	, (...)
 View the complete list with 1 more genes 
Specificity
 24 % 
Genes
 72 % | 
|  APOE, APP, PSEN1, PSEN2. NextGeneDx.Complete sequencing by NGS. By Instituto de Medicina Genomica Instituto de Medicina Genomica (Spain). 
APOE, APP, PSEN1, PSEN2
 
Specificity
 75 % 
Genes
 43 % | 
|  APP. Complete sequencing. By Instituto de Medicina Genomica Instituto de Medicina Genomica (Spain). 
APP
 
Specificity
 100 % 
Genes
 15 % | 
|  , APP. Complete sequencing. By Instituto de Medicina Genomica Instituto de Medicina Genomica (Spain). 
APP
 
Specificity
 100 % 
Genes
 15 % | 
|  APP. MLPA testing. By Instituto de Medicina Genomica Instituto de Medicina Genomica (Spain). 
APP
 
Specificity
 100 % 
Genes
 15 % | 
You can get up to 166 more panels with our dedicated tool
Learn moreSources and references
You can check the following sources for additional information.
ORPHANET Rare Disease Symptoms CheckerIf you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like DYSOSTEOSCLEROSIS EPILEPSY, IDIOPATHIC GENERALIZED; EIG CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2CC; CMT2CC